medigraphic.com

2014, Number 5

<< Back Next >>

Cir Cir 2014; 82 (5)

Efficacy of topical ketorolac for improving visual function after photocoagulation in diabetic patients with focal macular edema

Razo Blanco-Hernández DM, Lima-Gómez V, Asbun-Bojalil J

Language: Spanish
References: 34
Page: 477-488
PDF size: 495.19 Kb.


ABSTRACT

Background: Photocoagulation reduces the incidence of visual loss in diabetic patients with focal macular edema, but it can induce it for 6 weeks after treatment and produces visual improvement in some cases. Topical ketorolac may reduce the inflammation caused by photocoagulation and improve visual outcome.
Purpose: To determine the efficacy of topical ketorolac for improving visual function after photocoagulation in diabetic patients with focal macular edema.
Methods: An experimental, comparative, prospective, longitudinal study in diabetic patients with focal macular edema was conducted. Eyes were randomized into two groups of topical treatment for 3 weeks after photocoagulation (A: ketorolac, B: placebo). Best corrected visual acuity before and after treatment was compared in each group (paired t test), and the proportion of eyes with visual improvement was compared between groups ( χ2). The evaluation was repeated after stratifying for initial visual acuity (≥ 0.5, ‹ 0.5).
Results: There were 105 eyes included. In group A (n= 46) mean visual acuity changed from 0.50 to 0.58 (p= 0.003), and from 0.55 to 0.55 in group B (n= 59, p= 0.83); mean percent change was 22.3% in group A and 3.5% in group B (p= 0.03). Visual improvement was identified in 25 eyes from group A (54.3%) and 19 from group B (32.2%, p= 0.019, RR 1.65); the difference only persisted when initial visual acuity was ≥ 0.5 (10 [40%], group A, 5 [14.7%], group B, p= 0.02, RR 2.72).
Conclusion: Topical ketorolac was more effective than placebo to improve best corrected visual acuity in diabetic patients with focal macular edema.


REFERENCES

  1. Early Treatment Diabetic Retinopathy Study research group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 1985;103:1796-1806.

  2. Asociación Mexicana de Retina, Sociedad Mexicana de Oftalmología and Asociación Panamericana de Oftalmología. Resultados del Día Panamericano de detección de retinopatía diabética (3 de julio de 1999, día D). Rev Mex Oftalmol 2005;79:88-92.

  3. American Academy of Ophthalmology. Retina Panel. Diabetic Retinopathy. Preferred practice patterns 2008:3-24.

  4. Bandello F. Fluorescein angiography in laser treatment of diabetic macular edema. Ophthalmology 2001;108:236.

  5. Brown JC, Solomon SD, Bressler SB, Schachat AP, DiBernardo C, Bressler NM. Detection of diabetic foveal edema: contact lens biomicroscopy compared with optical coherence tomography. Arch Ophthalmol 2004;122:330-335.

  6. Campbell RJ, Coupland SG, Buhrmann RR, Kertes PJ. Optimal Optical Coherence Tomography-Based Measures in the Diagnosis of Clinically significant Macular Edema. Retinal Volume vs Foveal Thickness. Arch Ophthalmol 2007;125(5):619-623.

  7. Early Treatment Diabetic Retinopathy Study Research Group. Early Photocoagulation for Diabetic Retinopathy. ETDRS Report Number 9. Ophthalmology 1991;98(5):766- 785.

  8. Ilavska M. The effect of photocoagulation on visual acuity in diabetic patients suffering from diabetic macular edema and diabetic retinopathy. Bratisl Lek Listy 2009;110(7):419- 422.

  9. Zaidi ZA, Jacob MK. Effect of macular photocoagulation on visual acuity of Omani patients with clinically significant macular edema. Oman J Ophthalmol 2009;2(2):62-66.

  10. Lima-Gómez V, Razo Blanco-Hernández DM. Características asociadas con mejoría visual después de la 2012;80(4):311-319.

  11. Tsujikawa A, Kiryu J, Dong J, Yasukawa T, Suzuma I, Takagi H, et al. Quantitative Analysis of Diabetic Macular Edema After Scatter Laser Photocoagulation With the Scanning Retinal thickness Analyzer. Retina 1999;19(1):59-64.

  12. Shimura M, Yasuda K, Nakazawa T, Kano T, Ohta S, Tamai M. Quantifying alterations of macular thickness before and after panretinal photocoagulation in patients with severe diabetic retinopathy and good vision. Ophthalmology 2003;110(12):2386-2394.

  13. Walters T, Raizman M, Ernest P, Gayton J, Lehmann R. In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac. J Cataract Refract Surg 2007;33(9):1539-1545.

  14. Kim SJ, Flach AJ, Jampol LM. Nonsteroidal Anti-inflammatory Drugs in Ophthalmology. Surv Ophthalmol 2010;55(2):108-133.

  15. Bucci FA Jr, Waterbury LD, Amico LM. Prostaglandin E2 Inhibition and Aqueous Concentration of Ketorolac 0.4% (Acular LS) and Nepafenac 0.1% (Nevanac) in Patients Undergoing Phacoemulsification. Am J Ophthalmol 2007;144(1):146-147.

  16. Sandoval HP, Fernández de Castro LE, Vroman DT, Solomon KD. A review of the use of ketorolac tromethamine 0.4% in the treatment of post-surgical inflammation following cataract and refractive surgery. Clin Ophthalmol 2007;1(4):367- 371.

  17. Schoenberger SD, Kim SJ. Nonsteroidal Anti-Inflammatory Drugs for Retinal Disease. Int J Inflam 2013;2013:1-8.

  18. Attar M, Schiffman R, Borbridge L, Farnes Q, Welty D. Ocular pharmacokinetics of 0.45% ketorolac tromethamine. Clin Ophthalmol 2010;4:1403-1408.

  19. Lima VG. Efecto de ketorolaco tópico en la reducción del grosor retiniano, en pacientes tratados con fotocoagulación por edema macular diabético. Rev Mex Oftalmol 2008;82(1):28-33.

  20. Polito A, Del Borrello M, Polini G, Furlan F, Isola M, Bandello F. Diurnal Variation in Clinically Significant Diabetic Macular Edema Measured By the Stratus Oct. Retina 2006;26(1):14- 20.

  21. Sadda SR, Wu Z, Walsh AC, Richine L, Dougall J, Cortez R, et al. Errors in Retinal Thickness Measurements Obtained by Optical Coherence Tomography. Ophthalmology 2006;113(2):285-293.

  22. Browning DJ, Glassman AR, Aiello LP, Bressler NM, Bressler SB, Danis RP, et al. Optical Coherence Tomography Measurements and Analysis Methods in Optical Coherence Tomography Studies of Diabetic Macular Edema. Ophthalmology 2008;115(8):1366-1371.e1.

  23. Lewis H, Ryan SJ. Medical and surgical retina. St Louis: Mosby-Yearbook, 1994. p. 251-261.

  24. Nonaka A, Kiryu J, Tsujikawa A, Yamashiro K, Nishijima K, Kamizuru H, et al. Inflammatory Response after Scatter Laser Photocoagulation in Nonphotocoagulated Retina. Invest Ophthalmol Vis Sci 2002;43(4):1204-1209.

  25. Toth CA, Birngruber R, Boppart SA, Hee MR, Fujimoto JG, DiCarlo CD, et al. Argon laser retinal lesions evaluated in vivo by optical coherence tomography. Am J Ophthalmol 1997;123(2):188-198.

  26. Lima-Gómez V, Razo Blanco-Hernández DM, Asbun- Bojalil J. Efecto de la fotocoagulación focal sobre el grosor del punto central en edema macular diabético. Cir Cir 2011;79(5):395-401.

  27. Browning DJ, Glassman AR, Aiello LP, Beck RW, Brown DM, Fong DS, et al. Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. Ophthalmology 2007;114(3):525-536.

  28. Ehrlich R, Harris A, Ciulla TA, Kheradiya N, Winston DM, Wirostko B. Diabetic macular oedema: physical, physiological and molecular factors contribute to this pathological process. Acta Ophthalmol 2010;88(3):279-291.

  29. Bertoni AG, Burke GL, Owusu JA, Carnethon MR, Vaidya D, Barr RG, et al. Inflammation and the Incidence of Type 2 Diabetes. The Multi-Ethnic Study of Atherosclerosis (MESA). Diabetes Care 2010;33(4):804-810.

  30. Kim SJ, Toma HS, Barnett JM, Penn JS. Ketorolac inhibits choroidal neovascularization by suppression of retinal VEGF. Exp Eye Res 2010;91(4):537-543.

  31. El-Remessy AB, Bartoli M, Platt DH, Fulton D, Caldwell RB. Oxidative stress inactivates VEGF survival signaling in retinal endothelial cells via PI 3-kinase tyrosine nitration. J Cell Sci 2005;118(1):243-252.

  32. Razo-Blanco Hernández DM, Lima-Gómez V. Reducción de la sensibilidad foveal en la retina no engrosada en ojos con edema macular diabético. Boletín Informativo CCINSHAE 2013:57-58.

  33. Chidlow G, Shibeeb O´Sam, Plunkett M, Casson RJ, Wood JPM. Glial Cell and Inflammatory Responses to Retinal Laser Treatment: Comparison of a Conventional Photocoagulator and a Novel, 3-Nanosecond Pulse Laser. Invest Ophthalmol Vis Sci 2013;54(3):2319-2332.

  34. Vujosevic S, Martini F, Convento E, Longhin E, Kotsafti O, Parrozzani R, et al. Subthreshold Laser Therapy for Diabetic Macular Edema: Metabolic and Safety Issues. Current Medicinal Chemistry 2013;20(26):3267-3271.




2020     |     www.medigraphic.com